These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36828794)

  • 21. Size Dependence Unveiling the Adsorption Interaction of High-Density Lipoprotein Particles with PEGylated Gold Nanoparticles in Biomolecular Corona Formation.
    Jang GJ; Jeong JY; Kang J; Cho W; Han SY
    Langmuir; 2021 Aug; 37(32):9755-9763. PubMed ID: 34347501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of ligand composition on the in vivo fate of multidentate poly(ethylene glycol) modified gold nanoparticles.
    Liu X; Huang N; Wang H; Li H; Jin Q; Ji J
    Biomaterials; 2013 Nov; 34(33):8370-81. PubMed ID: 23932246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Physiologically-Based Kinetics Modelling to Reliably Predict Internal Concentrations of the UV Filter, Homosalate, After Repeated Oral and Topical Application.
    Najjar A; Schepky A; Krueger CT; Dent M; Cable S; Li H; Grégoire S; Roussel L; Noel-Voisin A; Hewitt NJ; Cardamone E
    Front Pharmacol; 2021; 12():802514. PubMed ID: 35058784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles.
    Deng L; Liu H; Ma Y; Miao Y; Fu X; Deng Q
    Toxicol Appl Pharmacol; 2019 Dec; 384():114765. PubMed ID: 31669777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances.
    Minnema J; Borgos SEF; Liptrott N; Vandebriel R; Delmaar C
    Drug Deliv Transl Res; 2022 Sep; 12(9):2132-2144. PubMed ID: 35551616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of physiologically based kinetic (PBK) modeling to study interindividual human variation and species differences in plasma concentrations of quercetin and its metabolites.
    Boonpawa R; Moradi N; Spenkelink A; Rietjens IM; Punt A
    Biochem Pharmacol; 2015 Dec; 98(4):690-702. PubMed ID: 26441251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of gold nanoparticles with Doxorubicin mediated by supramolecular chemistry.
    Marcelo G; Kaplan E; Tarazona MP; Mendicuti F
    Colloids Surf B Biointerfaces; 2015 Apr; 128():237-244. PubMed ID: 25697809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.
    Najjar A; Punt A; Wambaugh J; Paini A; Ellison C; Fragki S; Bianchi E; Zhang F; Westerhout J; Mueller D; Li H; Shi Q; Gant TW; Botham P; Bars R; Piersma A; van Ravenzwaay B; Kramer NI
    Arch Toxicol; 2022 Dec; 96(12):3407-3419. PubMed ID: 36063173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice.
    Abu-Dief AM; Alsehli M; Awaad A
    Histochem Cell Biol; 2022 Jun; 157(6):641-656. PubMed ID: 35157114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A physiologically based kinetic modeling of ethyl tert-butyl ether in humans-An illustrative application of quantitative structure-property relationship and Monte Carlo simulation.
    Watanabe-Matsumoto S; Yoshida K; Meiseki Y; Ishida S; Hirose A; Yamada T
    J Toxicol Sci; 2022; 47(2):77-87. PubMed ID: 35110473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effects of Polymer Coating of Gold Nanoparticles on Oxidative Stress and DNA Damage.
    Sen GT; Ozkemahli G; Shahbazi R; Erkekoglu P; Ulubayram K; Kocer-Gumusel B
    Int J Toxicol; 2020; 39(4):328-340. PubMed ID: 32483993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery.
    Rahme K; Guo J; Holmes JD; O'Driscoll CM
    Colloids Surf B Biointerfaces; 2015 Nov; 135():604-612. PubMed ID: 26322474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-β peptide and surface reorganization.
    Le Droumaguet B; Souguir H; Brambilla D; Verpillot R; Nicolas J; Taverna M; Couvreur P; Andrieux K
    Int J Pharm; 2011 Sep; 416(2):453-60. PubMed ID: 21251960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mammalian Cells Exocytose Alkylated Gold Nanoparticles
    Ho LWC; Chan CKW; Han R; Lau YFY; Li H; Ho YP; Zhuang X; Choi CHJ
    ACS Nano; 2022 Feb; 16(2):2032-2045. PubMed ID: 35137580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sub-10 nm Substrate Roughness Promotes the Cellular Uptake of Nanoparticles by Upregulating Endocytosis-Related Genes.
    Yin B; Ho LWC; Liu S; Hong H; Tian XY; Li H; Choi CHJ
    Nano Lett; 2021 Feb; 21(4):1839-1847. PubMed ID: 33586442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive performance of next generation human physiologically based kinetic (PBK) models based on in vitro and in silico input data.
    Punt A; Louisse J; Beekmann K; Pinckaers N; Fabian E; Van Ravenzwaay B; Carmichael PL; Sorrell I; Moxon TE
    ALTEX; 2022; 39(2):221–234. PubMed ID: 35064272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically based kinetic modeling of the bioactivation of myristicin.
    Al-Malahmeh AJ; Al-Ajlouni A; Wesseling S; Soffers AE; Al-Subeihi A; Kiwamoto R; Vervoort J; Rietjens IM
    Arch Toxicol; 2017 Feb; 91(2):713-734. PubMed ID: 27334372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations.
    Punt A; Bos P; Hakkert B; Louisse J
    ALTEX; 2023; 40(2):237–247. PubMed ID: 35901496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary fate and consequences of transferrin-functionalized gold nanoparticles.
    Konduru NV; Velasco-Alzate K; Adduri S; Zagorovsky K; Diaz-Diestra D; Fisol F; Sanches M; Ndetan H; Brain JD; Molina RM
    Nanotheranostics; 2021; 5(3):309-320. PubMed ID: 33732602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orthogonal analysis of functional gold nanoparticles for biomedical applications.
    Tsai DH; Lu YF; DelRio FW; Cho TJ; Guha S; Zachariah MR; Zhang F; Allen A; Hackley VA
    Anal Bioanal Chem; 2015 Nov; 407(28):8411-22. PubMed ID: 26362156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.